Baltimore, MARYLAND29 Active Studies

Alzheimers Disease Clinical Trials in Baltimore, MARYLAND

Find 29 actively recruiting alzheimers disease clinical trials in Baltimore, MARYLAND. Connect with local research sites and explore new treatment options.

29
Active Trials
25
Sponsors
5,313
Enrolling

Recruiting Alzheimers Disease Studies in Baltimore

RecruitingBaltimore, MARYLANDNCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

740 participants
Daiichi Sankyo
View Study Details
RecruitingBaltimore, MARYLANDNCT05094336

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and ...

649 participants
Amgen
View Study Details
RecruitingBaltimore, MARYLANDNCT04143711

Study of DF1001 in Patients with Advanced Solid Tumors

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase ...

378 participants
Dragonfly Therapeutics
View Study Details
RecruitingBaltimore, MARYLANDNCT05123482

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

370 participants
AstraZeneca
View Study Details
RecruitingBaltimore, MARYLANDNCT06790966

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherap...

351 participants
PDS Biotechnology Corp.
View Study Details
RecruitingBaltimore, MARYLANDNCT06385080

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...

247 participants
Janssen Research & Development, LLC
View Study Details
RecruitingBaltimore, MARYLANDNCT06130553

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

234 participants
AstraZeneca
View Study Details
RecruitingBaltimore, MARYLANDNCT04915183

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of...

224 participants
National Institute on Deafness and Other Communication Disorders (NIDCD)
View Study Details
RecruitingBaltimore, MARYLANDNCT05966194

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers....

216 participants
EpicentRx, Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT04421248

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high leve...

214 participants
Donald Gilbert, MD, MS, FAAN, FAAP
View Study Details
RecruitingBaltimore, MARYLANDNCT06525571

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method...

200 participants
Johns Hopkins University
View Study Details
RecruitingBaltimore, MARYLANDNCT05933265

Study of LP-184 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy ...

175 participants
Lantern Pharma Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT05543681

Clinical Trial on Agitation in Alzheimer's Dementia

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild t...

164 participants
IGC Pharma, LLC
View Study Details
RecruitingBaltimore, MARYLANDNCT04775485

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...

141 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT04503265

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dos...

122 participants
AtlasMedx, Incorporated
View Study Details
RecruitingBaltimore, MARYLANDNCT05644262

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study ...

120 participants
University of Southern California
View Study Details
RecruitingBaltimore, MARYLANDNCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

120 participants
Volastra Therapeutics, Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT05262023

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses...

106 participants
Denali Therapeutics Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT06144645

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS....

102 participants
Foundation for Prader-Willi Research
View Study Details
RecruitingBaltimore, MARYLANDNCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingBaltimore, MARYLANDNCT05312671

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the...

63 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingBaltimore, MARYLANDNCT03317158

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), th...

55 participants
Noah Hahn, M.D.
View Study Details
RecruitingBaltimore, MARYLANDNCT03914794

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with ...

43 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingBaltimore, MARYLANDNCT03607890

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 ...

42 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingBaltimore, MARYLANDNCT04789044

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is s...

40 participants
Major Extremity Trauma Research Consortium
View Study Details
RecruitingBaltimore, MARYLANDNCT05819866

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy....

40 participants
Minoryx Therapeutics, S.L.
View Study Details
RecruitingBaltimore, MARYLANDNCT06637423

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having cert...

32 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBaltimore, MARYLANDNCT03266627

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents...

20 participants
New York Medical College
View Study Details
RecruitingBaltimore, MARYLANDNCT05977907

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly ...

15 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details

About Alzheimers Disease Clinical Trials in Baltimore

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 29 alzheimers disease clinical trials recruiting participants in Baltimore, MARYLAND. These studies are seeking a combined 5,313 participants. Research is being sponsored by Daiichi Sankyo, Amgen, Dragonfly Therapeutics and 22 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in Baltimore — FAQ

Are there alzheimers disease clinical trials in Baltimore?

Yes, there are 29 alzheimers disease clinical trials currently recruiting in Baltimore, MARYLAND. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baltimore?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.

Are clinical trials in Baltimore free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 29 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated March 2, 2026 from ClinicalTrials.gov